文献速递肝病

非酒精性脂肪性肝炎中体重变化与奥贝胆酸相关的临床和代谢效应

Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
PubMed 文献 · Aliment Pharmacol Ther · 2018-01-14

该事后分析基于72周随机对照试验中200例有基线和治疗终点肝活检的非酒精性脂肪性肝炎患者,比较体重下降与奥贝胆酸治疗对临床和代谢指标的影响。奥贝胆酸组体重下降比例44% vs 安慰剂组32%(P=0.08),两组体重下降者组织学均改善更多,但奥贝胆酸消除了体重下降对碱性磷酸酶、血脂和血糖的有利效应。

要点

  • 奥贝胆酸组体重下降44%(45/102)vs 安慰剂组32%(31/98),P=0.08。
  • 两组体重下降者NAFLD活动度评分改善均优于无体重下降者。
  • 体重下降者中,奥贝胆酸组碱性磷酸酶、总胆固醇、LDL胆固醇和HbA1c变化与安慰剂组方向相反。

核心结论

  • 奥贝胆酸可使高达44%的非酒精性脂肪性肝炎患者体重下降,奥贝胆酸治疗与体重下降对血清转氨酶和组织学有叠加获益。
  • 但安慰剂组中体重下降对碱性磷酸酶、血脂和血糖的有利效应在奥贝胆酸治疗中缺失或逆转。
  • 这些发现强调评估非酒精性脂肪性肝炎新疗法伴随代谢效应的重要性。

研究设计与样本

  • 72周随机对照试验的事后分析,仅纳入200例有基线和治疗终点肝活检的非酒精性脂肪性肝炎患者。
  • 体重下降定义为治疗结束时较基线相对下降2%或以上。

主要发现

  • 体重下降发生于奥贝胆酸组44%(45/102)和安慰剂组32%(31/98),P=0.08。
  • NAFLD活动度评分在体重下降者中改善更多:奥贝胆酸组-2.4 vs -1.2(P<0.001),安慰剂组-1.2 vs -0.5(P=0.03)。
  • ALT在体重下降者中改善:奥贝胆酸组-43 vs -34 U/L(P=0.12),安慰剂组-29 vs -10 U/L(P=0.02)。
  • 体重下降者中,奥贝胆酸组 vs 安慰剂组:碱性磷酸酶+21 vs -12 U/L(P<0.001),总胆固醇+13 vs -14 mg/dL(P=0.02),LDL胆固醇+18 vs -12 mg/dL(P=0.01),HbA1c +0.1 vs -0.4%(P=0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In a 72-week, randomised controlled trial of obeticholic acid (OCA) in non-alcoholic steatohepatitis (NASH), OCA was superior to placebo in improving serum ALT levels and liver histology. OCA therapy also reduced weight. AIMS: Because weight loss by itself can improve histology, to perform a post hoc analysis of the effects of weight loss and OCA treatment in improving clinical and metabolic features of NASH. METHODS: The analysis was limited to the 200 patients with baseline and end-of-treatment liver biopsies. Weight loss was defined as a relative decline from baseline of 2% or more at treatment end. RESULTS: Weight loss occurred in 44% (45/102) of OCA and 32% (31/98) of placebo-treated patients (P = 0.08). The NAFLD Activity score (NAS) improved more in those with than without weight loss in both the OCA- (-2.4 vs -1.2, P<0.001) and placebo-treated patients (-1.2 vs -0.5, P = 0.03). ALT levels also improved in those with vs without weight loss in OCA- (-43 vs -34 U/L, P = 0.12) and placebo-treated patients (-29 vs -10 U/L, P = 0.02). However, among those who lost weight, OCA was associated with opposite effects from placebo on changes in alkaline phosphatase (+21 vs -12 U/L, P<0.001), total (+13 vs -14 mg/dL, P = 0.02) and LDL cholesterol (+18 vs -12 mg/dL, P = 0.01), and HbA1c (+0.1 vs -0.4%, P = 0.01). CONCLUSIONS: OCA leads to weight loss in up to 44% of patients with NASH, and OCA therapy and weight loss have additive benefits on serum aminotransferases and histology. However, favourable effects of weight loss on alkaline phosphatase, lipids and blood glucose seen in placebo-treated patients were absent or reversed on OCA treatment. These findings stress the importance of assessing concomitant metabolic effects of new therapies of NASH. Clinical trial number: NCT01265498.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hameed B, Terrault NA, Gill RM, et al. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2018. PMID: 29333665. doi:10.1111/apt.14492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。